Personal Introduction:

Dr. Yu Chen obtained his Master’s degree in Medicinal Chemistry from China Pharmaceutical University in 2017 and his Ph.D. in Pharmaceutics from Fudan University in 2021, and then pursued postdoctoral training at the School of Pharmacy, University of Wisconsin-Madison, USA. He joined the College of Basic Medical Sciences at Shanghai Jiao Tong University as Principal Investigator in March 2026 and currently leads the Laboratory of Molecular Design and Translational Therapy. His team aims to integrate molecular design with delivery strategies to engineer innovative therapeutics and tools addressing current clinical challenges. As the first author, Dr. Chen has published his research findings in high-impact journals, including Nature Biotechnology, Nature Reviews Clinical Oncology, Journal of the American Chemical Society (JACS), and Chemical Society Reviews. He has also filed multiple PCT international patents, U.S. patents, and Chinese invention patents. He is a recipient of the NSFC Excellent Young Scientists Fund (Overseas) and the Shanghai Magnolia Talent Plan (Pujiang Program). Dr. Chen serves as the Youth Editor of Biomedical Technology and a Young Editorial Board Member of Materials Today Bio, Exploration, and VIEW.

Scientific Research Projects:

• National Natural Science Fund for Excellent Young Scientists Fund Program (Overseas), 2027-2029, Principal Investigator.

• Shanghai Magnolia Talent Plan (Pujiang Program), 2027-2029, Principal Investigator.

• Start-up Package from Shanghai Jiao Tong University School of Medicine, 2026-2032, Principal Investigator.

Publications:

1. Yu Chen, Tyler Wolter, Zhen Gu*, Quanyin Hu*. Engineering platelets as cancer therapeutics. Nature Reviews Clinical Oncology, 2026; DOI: 10.1038/s41571-026-01122-5.

2. Yu Chen, Samira Pal, Wen Li, Fengyuan Liu, Sichen Yuan, Quanyin Hu*. Engineered platelets as targeted protein degraders and application to breast cancer models. Nature Biotechnology, 2025; 43: 1800-1812. DOI: 10.1038/s41587-024-02494-8.

3. Yu Chen, Fengyuan Liu, Samira Pal, Quanyin Hu*. Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design. Chemical Society Reviews, 2024; 53: 9582-9608. DOI: 10.1039/d4cs00411f.

4. Yu Chen, Wen Li, Song Kwon, Yixin Wang, Zhaoting Li, Quanyin Hu*. Small-molecule ferritin degrader as a pyroptosis inducer. Journal of the American Chemical Society (JACS), 2023; 145: 9815-9824. DOI: 10.1021/jacs.3c01852.

5. Yu Chen, Samira Pal, Quanyin Hu*. Cell-based relay delivery strategy in biomedical applications. Advanced Drug Delivery Reviews, 2023; 198: 114871. DOI: 10.1016/j.addr.2023.114871.

6. Yu Chen, Ira Tandon, William Heelan, Yixin Wang, Weiping Tang*, Quanyin Hu*. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation. Chemical Society Reviews, 2022; 51: 5330-5350. DOI: 10.1039/d1cs00762a.